focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looking at how SP dropped this morning are they accumulating for the presentation
Fingers crossed they reveal some gems GLA
Rises on AIM rarely last more than a single trading session now. I used to quite enjoy buying on a Monday and selling on a Friday but it's been a long time since that happened
Ignore the troll !
Markets are in turmoil
Trolls derampers etc are taking advantage this
Hold your nerve!
Maybe??? Back to Friday's close price again perhaps???. It's as if there hasn't been 2 decent RNS's. I despair!!!
Suckers !
The trades aren’t all reporting correctly owing to the margins and volatility, so the SP isn’t rightly reflected. Just means investors get a bargain entry price IMO :)
I thought it was a great RNS, surprised we are not trading much higher.
Hopefully the hord is gone now...
12-Oct-22 08:36:35 5.79 302,697 Buy* 5.50 5.80 17.53k
$160.5m license award
Summary from Mondays RNS for new investors:
“Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications.”
noobs need to stop interpreting 'buys as sells' as anything other than a deliberate anomaly of trading. it certainly doesn't imply some illuminati skullduggery triggering a bagging by lunchtime.
this is frustratingly sitting between 5.8 > 5.5. i hope that the presentation says something more than just repeating this week's news but it can't be anything more than highlighting what the news means for holders.
sorry, many buys marked as sells, I meant
I bought two tranches of shares yesterday, both buys showed up as sales.
Same happening today and many of those sells are clearly buys.
When will the MM’s get a system that accurately reports trades?
Expecting a big day, providing the systems fix their technical issues.
Many sells marked as buys. I think the MMs are taking the p1ss with this price. They won't let it go
Proactive Investors:
Evgen Pharma PLC (AIM:EVG) said changes to its glioblastoma programme are expected to extend its cash runway by more than a year.
It said it will pull the trigger on the trial of its lead asset, SFX-01, in healthy volunteers to assess its pharmacokinetic its pharmacodynamic properties.
Specifically, it wants to see how the new coating for the pill performs. Top-line data are expected in the first half of next year.
It has also taken the decision to embark on an investigator-sponsored clinical study (ISS) to assess the drug’s potential in glioblastoma, a form of brain cancer while carrying out further pre-clinical work.
Evgen said it had been advised to take this route by experts in the field, and added the approach would allow it to ‘de-risk’ a subsequent phase II trial.
It will allow researchers to assess with ‘more clarity’ how the active ingredient, sulforaphane. enters the tumour and interacts with it at a molecular level.
Carrying out the ISS will be Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre, in the Netherlands, who is at the forefront of glioblastoma research.
The company said it would look for partnering opportunities while the ISS was being undertaken.
The impact of this change of tack is to push out the cash runway to at least the end of the fourth quarter of 2024 rather than the third quarter of next year. This will extend into 2025 if a deal inked with Swiss drug developer Stalicla earlier this week generates the envisaged milestone payments.
“We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners," said Evgen chief executive Dr Huw Jones.
I've just got in early and got 83 135 more shares at 5.99p.
Cheap at the price.
Can't wait to watch the presentation today at 1pm.
GLA.
An outstanding and exciting update that vindicates my plan to hold at least through through 2023.
This should already by 10+ now. Net of cash we're worth just £7-8m! The potential here is simply mind blowing. This could easily be worth 100s of millions within a few years.
All IMHO DYOR
Happy
http://mastersinvest.com/patiencequotes
Not something I am good at yet, I trade too much and too often!
EVG seems like a golden opportunity to buy and hold.
Great RNs. Also check out PYC. Contract with cancer research Uk today only with a £2 mill mcap.
Just sayin
Price gaped up again on opening - not good IMHO
Covers all major aspects:
-trial
-time frame
-cash runway
-non dilutive fundinv
-deepening ties with a major partner.
Very pleased.
All we need now is some Tr-1’s
And management buys …
One Major consideration here is that if the Market fails to value EVGEN fairly, and that includes the huge potential of SFX-01 in Brain, Breast & Colorectal Cancers aswell as the recently announced $160M agreement with Stalicia SA then the Company is likely to be bought out on the cheap.
I’m confident that ‘Big pharma’ will be taking a great interest in what Evgen are developing here.
Oral Tablet Formulation too……..
Still the possibility of further RNS’s such as majors accumulating more shares, including AXA and Octopus :)